MedTrace Logo

Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

NCT02114658 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-08-03

No results posted yet for this study

Summary

The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).

Conditions

  • Thyroid Carcinoma

Interventions

DRUG

Sorafenib (Nexavar,BAY43-9006)

Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-15
Primary Completion
2015-02-23
Completion
2016-08-02

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02114658 on ClinicalTrials.gov